Interferon-Mediated Regression of Fibrosis During Antiviral Therapy for Chronic Hepatitis C in Different Variants of IL28B Gene Polymorphism
Keywords:chronic hepatitis C, fibrosis, gene IL28b, virologic response
The article considers the relationship between the degree of reduction of HCV-induced liver fibrosis by the end of antiviral therapy (AVT) for chronic hepatitis C (CHC) and the main variants of IL28b gene polymorphism. Materials and Methods. Retrospectively we analyzed the outcomes of treatment of 324 patients who received standard antiviral therapy (a combination of pegylated interferons PegIFN-alpha2b or PegIFN-alpha2a and ribavirin) for CHC genotype 1b. The total duration of treatment was 12 months. We evaluated three types of virologic response: rapid (RVR, 4th week of AVT), early (EVR, 12th week of AVT) and sustained (SVR, 24th week after the AVT). Results and Discussion. All types of detected changes of fibrosis stages by the end of antiviral treatment in comparison with baseline values were distributed into the following groups : 1 — a significant reduction of fibrosis (25 % of treated patients), 2 — moderate decrease in fibrosis (64 % patients), 3 — unchanged degree of fibrosis (7.6 %), increased fibrosis (3.4 %). A comparison of fibrosis dynamics during antiviral therapy was carried out in the two groups of patients: without (N = 110) and with (N = 214) T-allele of the gene IL28b. The most significant decrease in the degree of fibrosis detected among patients with favorable CC gene IL28b variant, because exactly in this group of patients the frequency of SVR was highest. Among those who have reached sustained aviremia, the lowest degree of reduction of fibrosis was found in T-allele carriers of the gene IL28b. Conclusions. The findings suggest that not all patients with CHC who achieved sustained virologic response escape the risks associated with the effects of viral persistence of HCV.
Hepatocellular carcinoma after sustained virologic response in hepatitis C patients without cirrhosis on a pre-treatment liver bio-psy / Justin L. Sewell, Kristine M. Stick, Alexander Monto // Eur. J. Gastroenterol. Hepatol. — 2009. — № 21(2). — P. 225-229.
Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection / Charlton M.R., Thompson A., Veldt B.J., Watt K., Tillmann H., Poterucha J.J., Heimbach J.K., Goldstein D., McHutchison J. // Hepatology. — 2011. — 53(1). — P. 317-324.
Role of IL28B polymorphism in the development of hepatitis C virus-induced hepatocellular carcinoma, graft fibrosis, and posttransplant antiviral therapy / Eurich D., Boas-Knoop S., Bahra M., Neuhaus R., Somasundaram R., Neuhaus P., Neumann U., Seehofer D. // Transplantation. — 2012. — № 93(6). — P. 644-649.
Genomics and HCV infection: Progression of ﬁbrosis and treatment response / Emilie Estrabaud, Michel Vidaud, Patrick Marcellin, Tarik Asselah // Journal of Hepatology. — 2012. —
Vol. 57. — P. 1110-1125.
Bedossa P., Poynard T. An algorithm for the grading of acti-
vity in chronic hepatitis C. The METAVIR Cooperative Study Group // Hepatology. — 1996. — № 24(2). — P. 289-293.
Ngo Y., Munteanu M., Messous D., Charlotte F., Imbert-Bismut F., Thabut D., Lebray P., Thibault V., Benhamou Y., Moussalli J., Ratziu V., Poynard T. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C // Clin. Chem. — № 52 (10). — P. 1887-1896.
Copyright (c) 2016 ACTUAL INFECTOLOGY
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.